Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) live share price

Arrowhead Pharmaceuticals, Inc. share price in USD $26.03 & INR ₹2,204.61

$26.03

-0.12

(-0.46%)

View live Arrowhead Pharmaceuticals, Inc. share price in Dollar and Rupees. Guide to invest in Arrowhead Pharmaceuticals, Inc. from India. Also see the sentimental analysis on Indian investors investing in Arrowhead Pharmaceuticals, Inc.. Get details on the Indian mutual funds that are investing in Arrowhead Pharmaceuticals, Inc.. Get Analyst recommendations and forecasts along with all the Arrowhead Pharmaceuticals, Inc.'s financials.

Arrowhead Pharmaceuticals, Inc. share price movements

  • $25.71
    $27.25

    Day's Volatility :5.66%

  • $17.05
    $39.83

    52 Weeks Volatility :57.19%

Arrowhead Pharmaceuticals, Inc. Returns

PeriodArrowhead Pharmaceuticals, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
13.62%
-6.2%
0.0%
6 Months
5.73%
2.6%
0.0%
1 Year
4.41%
11.8%
0.0%
3 Years
-61.44%
13.3%
-19.8%

Arrowhead Pharmaceuticals, Inc. Key Statistics

in dollars & INR

Market Capitalization
$3.2B
Revenue TTM
$19.6M
EBITDA
$-529.8M
Earnings Per Share (EPS)
$-5.0
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.1%
Return On Equity TTM
-151.84%

How to invest in Arrowhead Pharmaceuticals, Inc. from India?

It is very easy for Indian residents to invest directly in Arrowhead Pharmaceuticals, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Arrowhead Pharmaceuticals, Inc. stock in both rupees (INR) and dollars (USD). Search for Arrowhead Pharmaceuticals, Inc. or ARWR on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Arrowhead Pharmaceuticals, Inc. or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Arrowhead Pharmaceuticals, Inc. shares which would translate to 0.033 fractional shares of Arrowhead Pharmaceuticals, Inc. as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Arrowhead Pharmaceuticals, Inc.

63.27%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Investment in Arrowhead Pharmaceuticals, Inc. from India has grown in the last 30 days as on Dec 2, 2024. 63.27% more purchase transactions for Arrowhead Pharmaceuticals, Inc. in the last 30 days versus the previous period.

116%

Period: Sep 2, 2024 to Dec 1, 2024. Change in 30 Days versus previous period

Search volume for Arrowhead Pharmaceuticals, Inc. on INDmoney from India has grown in the last 30 days as on Dec 2, 2024. 116% more investors are searching Arrowhead Pharmaceuticals, Inc. in the last 30 days versus the previous period.

Global Institutional Holdings in Arrowhead Pharmaceuticals, Inc.

  • BlackRock Inc

    12.62%

  • Vanguard Group Inc

    9.84%

  • venBio Select Advisor LLC

    7.15%

  • FMR Inc

    4.88%

  • State Street Corp

    4.70%

  • Slate Path Capital LP

    3.93%

Analyst Recommendation on Arrowhead Pharmaceuticals, Inc.

Buy

    75%Buy

    25%Hold

    0%Sell

Based on 20 Wall street analysts offering stock ratings for Arrowhead Pharmaceuticals, Inc.(by analysts ranked 0 to 5 stars)

Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
5
5
5
Sell
0
0
0

Analyst Forecast on Arrowhead Pharmaceuticals, Inc.

What analysts predicted

Upside of 74.35%

Current:

$26.03

Target:

$45.38

Insights on Arrowhead Pharmaceuticals, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.09M → 3.55M (in $), with an average decrease of 77.9% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -170.79M → -170.53M (in $), with an average increase of 0.2% per quarter
  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 47.6% return, outperforming this stock by 35.3%
  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.4% return, outperforming this stock by 101.0%

Arrowhead Pharmaceuticals, Inc. Technicals Summary

Sell

Neutral

Buy

Arrowhead Pharmaceuticals, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Arrowhead Pharmaceuticals, Inc. Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arrowhead Pharmaceuticals, Inc.
29.76%
5.73%
4.41%
-61.44%
-60.83%
Regeneron Pharmaceuticals, Inc.
-9.49%
-24.18%
-8.88%
18.12%
102.78%
Biontech Se
8.64%
15.09%
18.5%
-65.59%
454.0%
Alnylam Pharmaceuticals, Inc.
-6.25%
68.21%
46.39%
47.68%
107.47%
Vertex Pharmaceuticals Incorporated
-0.99%
-0.44%
33.51%
129.69%
109.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arrowhead Pharmaceuticals, Inc.
NA
NA
-1.32
-4.53
-1.52
-0.41
NA
2.66
Regeneron Pharmaceuticals, Inc.
18.66
18.66
1.12
44.91
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arrowhead Pharmaceuticals, Inc.
Buy
$3.2B
-60.83%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
102.78%
18.66
33.61%
Biontech Se
Buy
$28.9B
454.0%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$32.7B
107.47%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$119.6B
109.07%
32.84
-4.51%

Arrowhead Pharmaceuticals, Inc. Dividend announcements

  • Arrowhead Pharmaceuticals, Inc. Earnings

    Arrowhead Pharmaceuticals, Inc.’s price-to-earnings ratio stands at None

    Read More

About Arrowhead Pharmaceuticals, Inc.

arrowhead pharmaceuticals is a clinical stage, nasdaq listed (ticker arwr) company developing medicines that treat intractable diseases by silencing the genes that cause them. using a broad portfolio of rna chemistries and efficient modes of delivery, our therapies trigger the rna interference mechanism to induce rapid, deep and durable knockdown of target genes. rna interference, or rnai, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. our rnai-based therapeutics are at the leading edge of genetic-based therapy with the potential to bring life changing treatments for patients. our targeted rnai molecule (trimtm) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. the trim platform builds on more than a decade of work on actively targeted drug delivery and offers several advantages including simplified manufacturing
Organization
Arrowhead Pharmaceuticals, Inc.
Employees
525
CEO
Dr. Christopher R. Anzalone Ph.D.
Industry
Health Technology

Important FAQs about investing in Arrowhead Pharmaceuticals, Inc. from India :

What is Arrowhead Pharmaceuticals, Inc. share price today?

Arrowhead Pharmaceuticals, Inc. (ARWR) share price today is $26.03.

Can Indians buy Arrowhead Pharmaceuticals, Inc. shares?

Yes, Indians can invest in the Arrowhead Pharmaceuticals, Inc. (ARWR) from India.

With INDmoney, you can buy Arrowhead Pharmaceuticals, Inc. at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Arrowhead Pharmaceuticals, Inc. at zero transaction cost.

How can I buy Arrowhead Pharmaceuticals, Inc. shares from India?

It is very easy to buy Arrowhead Pharmaceuticals, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Arrowhead Pharmaceuticals, Inc. be purchased?

Yes, you can buy fractional shares of Arrowhead Pharmaceuticals, Inc. with INDmoney app.

What are the documents required to start investing in Arrowhead Pharmaceuticals, Inc. stocks?

To start investing in Arrowhead Pharmaceuticals, Inc., You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Arrowhead Pharmaceuticals, Inc.

Today’s highest price of Arrowhead Pharmaceuticals, Inc. (ARWR) is $27.25.

Today’s lowest price of Arrowhead Pharmaceuticals, Inc. (ARWR) is $25.71.

What is today's market capitalisation of Arrowhead Pharmaceuticals, Inc.

Today's market capitalisation of Arrowhead Pharmaceuticals, Inc. ARWR is 3.2B

What is the 52 Week High and Low Range of Arrowhead Pharmaceuticals, Inc.

  • 52 Week High

    $39.83

  • 52 Week Low

    $17.05

How much percentage Arrowhead Pharmaceuticals, Inc. is down from its 52 Week High?

Arrowhead Pharmaceuticals, Inc. (ARWR) share price is $26.03. It is down by 99% from its 52 Week High price of $39.83.

How much percentage Arrowhead Pharmaceuticals, Inc. is up from its 52 Week low?

Arrowhead Pharmaceuticals, Inc. (ARWR) share price is $26.03. It is up by 1% from its 52 Week Low price of $17.05.

What are the historical returns of Arrowhead Pharmaceuticals, Inc.?

  • 1 Month Returns

    29.76%

  • 3 Months Returns

    5.73%

  • 1 Year Returns

    4.41%

  • 5 Years Returns

    -60.83%

Who is the Chief Executive Officer (CEO) of Arrowhead Pharmaceuticals, Inc.

Dr. Christopher R. Anzalone Ph.D. is the current Chief Executive Officer (CEO) of Arrowhead Pharmaceuticals, Inc..